ACTRIMS/ECTRIMS 2020: Investigational Masitinib Shows Promise in Both Primary and Non-Active Secondary Progressive Multiple Sclerosis
The drug may help fill an unmet need in progressive MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.